REZUROCK (belumosudil)

Self-Administration – oral

Diagnosis considered for coverage:
  • Indicated for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy
Coverage Criteria:

For diagnosis of chronic GVHD:

  • Dose does not exceed one of the following:
    • 200 mg once daily; OR
    • 200 mg twice daily for patients using Rezurock concomitantly with one of the following: strong CYP3A inducer (e.g., carbamazepine, phenobarbital, phenytoin, rifampin) OR proton pump inhibitor (e.g., omeprazole, pantoprazole, lansoprazole); AND
  • Patient is 12 years of age or older; AND
  • Patient has a diagnosis of chronic graft-versus-host disease confirmed by chart note documentation; AND
  • Prescribed by or in consultation with a hematologist, oncologist, or physician experienced in the management of transplant patients; AND
  • Patient has a history of allogenic hematopoietic cell transplant (HCT); AND
  • Trial and failure of two or more lines of systemic therapy (e.g., corticosteroids, immunosuppressants, etc.); AND
  • Rezurock is not prescribed in combination with Imbruvica® or Jakafi®
Reauthorization Criteria:

For diagnosis of chronic GVHD:

  • Dose does not exceed one of the following:
    • 200 mg once daily; OR
    • 200 mg twice daily for patients using Rezurock concomitantly with one of the following: strong CYP3A inducer (e.g., carbamazepine, phenobarbital, phenytoin, rifampin) OR proton pump inhibitor (e.g., omeprazole, pantoprazole, lansoprazole); AND
  • Patient does not show evidence of progressive disease while on therapy; AND
  • Rezurock is not prescribed in combination with Imbruvica® or Jakafi®
Coverage Duration: 
  • Initial: 1 year
  • Reauthorization: 1 year
Authorization is not covered for the following: 

The use of this drug for indications not listed in this policy does not meet the coverage criteria established by the Western Health Advantage (WHA) Pharmacy and Therapeutics (P&T) Committee.

Additional Information: 
  • Recommended dose: 200 mg given orally once daily until progression of chronic GVHD that requires new systemic therapy
  • Increase the dosage of Rezurock to 200 mg twice daily when coadministered with strong CYP3A inducers or PPIs
  • Treatment with Rezurock has not been studied in patients with pre-existing severe renal or hepatic impairment. For patients with pre-existing severe renal or hepatic impairment, consider the risks and potential benefits before initiating treatment with Rezurock
  • Swallow Rezurock tablets whole. Do not cut, crush, or chew tablets.
  • Warning for embryo-fetal toxicity
  • Other systemic therapies for chronic GVHD: ruxolitinib (Jakafi), abatacept (Orencia), alemtuzumab (Campath), calcineurin inhibitors (e.g., tacrolimus, cyclosporine), etanercept (Enbrel), ECP (extracorporeal photopheresis), hydroxychloroquine, ibrutinib (Imbruvica), imatinib (Gleevec), IL-2, methotrexate, mTOR inhibitors (e.g., sirolimus), mycophenolate, pentostatin (Nipent), rituximab
Policy Updates:
  • 2/15/2022 – New policy approved by P&T.
References:
  • Rezurock Prescribing Information. Kadmon Pharmaceuticals, LLC. Warrendale, PA. July 2021.

Last review date: February 15, 2022

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone